about
Where Have All the Rodents Gone? The Effects of Attrition in Experimental Research on Cancer and StrokeLaunching invasive, first-in-human trials against Parkinson's disease: ethical considerationsEthical considerations of e-cigarette use for tobacco harm reductionHelsinki discords: FDA, ethics, and international drug trialsThreats to validity in the design and conduct of preclinical efficacy studies: a systematic review of guidelines for in vivo animal experimentsDistinguishing between exploratory and confirmatory preclinical research will improve translationA meta-analysis of threats to valid clinical inference in preclinical research of sunitinibWhy clinical translation cannot succeed without failureRisk of surgical delivery to deep nuclei: a meta-analysisThe attitudes of brain cancer patients and their caregivers towards death and dying: a qualitative studyTowards a global human embryonic stem cell bank: differential termination.Recent developments in gene transfer: risk and ethics.Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty.The therapeutic misconception at 25: treatment, research, and confusion.Protection at the cutting edge: the case for central review of human gene transfer researchExtending clinical equipoise to phase 1 trials involving patients: unresolved problemsThe risk-escalation model: a principled design strategy for early-phase trials.Research ethics. Beyond access vs. protection in trials of innovative therapies.Should preclinical studies be registered?Valuing risk: the ethical review of clinical trial safety.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic ReviewMedical research, risk, and bystanders.Increasing efficiency of preclinical research by group sequential designs.Can patient decision aids help people make good decisions about participating in clinical trials? A study protocolSetting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines.Ethics at phase 0: clarifying the issues.Ethics of cancer gene transfer clinical research.Is Participation in Cancer Phase I Trials Really Therapeutic?Ethics, ambiguity aversion, and the review of complex translational clinical trials.A canadian perspective on ethics review and neuroimaging: tensions and solutions.A theoretical framework for early human studies: uncertainty, intervention ensembles, and boundaries.Elements of informed consent and decision quality were poorly correlated in informed consent documents.Patient-Funded Trials: Opportunity or Liability?Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib.How do researchers decide early clinical trials?Do We Know Whether Researchers and Reviewers are Estimating Risk and Benefit Accurately?Tomorrow, interrupted? Risk, ethics, and medical advance in gene transfer.Design and Reporting of Targeted Anticancer Preclinical Studies: A Meta-Analysis of Animal Studies Investigating Sorafenib Antitumor Efficacy.Drug Development at the Portfolio Level Is Important for Policy, Care Decisions and Human Protections.Assessing risk/benefit for trials using preclinical evidence: a proposal.
P50
Q24288791-DD6C480E-66D2-41DF-A9AC-79975B0BB0B7Q24289526-C7A88C59-4241-4A19-94F2-C55F8E67A0E3Q26749334-60362360-0685-4540-9359-31F9D6DB24CAQ28305708-CCDD9AF0-B0B3-4BE8-A756-7384B68F06B7Q28534767-3F74A117-ACC6-417A-917B-B36DFA4B1799Q28538978-B64E38EA-120F-4EB1-954D-2237677525D8Q28606538-9E96DEC9-46F6-4E33-BDE8-19EEBBDD75DCQ28607112-0AA32E80-85D9-4182-9149-EAA8A70B0182Q30371423-E1C65B0C-9CF0-471D-8EFA-51FE99A526C4Q30837240-37F5FB56-32D5-4569-A748-FEAADE505C22Q33450354-BECBEEEB-4F89-456E-AB7A-04FEAA96A3EFQ33709989-09037945-4454-4461-A0BF-6299156BC34BQ33851241-EDAF981E-B88D-49EA-9F1F-82E2573C24ABQ34733687-163D7C4F-0EC5-4B9C-B350-70C24867EC69Q35558835-1B984CCE-DBA1-4686-80EE-0CAEC7B33E86Q35788038-9E8CC99C-893F-48BF-BA5A-3F80701332EDQ35788041-A41220D3-B951-47EA-8250-F826788969A6Q35893072-5A1C474C-F4BE-4F49-AA24-EB5E214B3A47Q35893083-02940CCF-93D1-4DB3-AE9C-7A8FCD62D3A5Q36090401-62B531D4-C446-489C-9590-6763715B07BAQ36270115-6D9D7A18-6623-41BB-A08F-84B37913F730Q36284292-0482C510-2F8F-49A4-8035-AEB46B7C00F7Q36304127-7597D737-4263-46EC-8A2A-9B351334ECFAQ36838989-84DD07DB-F6D4-4C5C-B836-4DBBF342FA9DQ37017086-40FD9984-5FF6-48B6-803B-1AC00B6DC602Q37030959-0E52964B-0EFF-4BA9-98A0-B90A3D46E84DQ37535812-3590212B-DCFF-47FB-9485-A648762B6490Q37660474-055F0E03-1C38-4D40-B584-0131C7914841Q37829465-E70E755E-DCC6-47BE-88E0-CD56790C898EQ37889474-BB50BA8F-F5D6-42EF-81B7-4CE63AC55B22Q38045514-FA4BDDB1-E146-4E17-B96F-14A8F15EF409Q38413226-2851E2C6-F6DA-43D0-A32A-CD351177B8ABQ38562564-1C85E12C-D1F5-4B77-A264-C86BB760B098Q38627885-D1DC8F21-9E3B-49D9-BF42-BF4DA7A10573Q38718855-0B2E2E29-9E78-4B16-95E6-24C4E76BBB63Q38838526-8C0401C7-86AF-4527-BE8E-1CD0120FD06EQ39502650-999557E7-5E25-4A6F-9A6E-245F7A7DAD91Q39710264-E2D40FEE-5951-42AD-A907-612F5220274DQ40072091-E67A5213-4BBB-4E44-A505-D7086CF378CAQ40925322-F99FDF82-BDD4-4D72-B54B-72E96FB89DB1
P50
description
researcher ORCID ID = 0000-0003-1614-6779
@en
wetenschapper
@nl
name
Jonathan Kimmelman
@ast
Jonathan Kimmelman
@en
Jonathan Kimmelman
@es
Jonathan Kimmelman
@nl
type
label
Jonathan Kimmelman
@ast
Jonathan Kimmelman
@en
Jonathan Kimmelman
@es
Jonathan Kimmelman
@nl
prefLabel
Jonathan Kimmelman
@ast
Jonathan Kimmelman
@en
Jonathan Kimmelman
@es
Jonathan Kimmelman
@nl
P214
P244
P21
P214
P244
n2009183132
P31
P496
0000-0003-1614-6779
P735
P7859
lccn-n2009183132